Medication info

Edis D Tablets

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Tripotassium Bismuth Dicitrate›200mg / 1 tabletRanitidine Hydrochloride›168mg / 1 tabletSucralfate Hydrate›600mg / 1 tablet
Manufacturer / importer
Eden Pharma Co., Ltd.
Appearance
Light green oblong film-coated tablets
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 201508508 · Approved 2015.12.30

This product's status changed to Approval withdrawn on 2024.03.19. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of gastrointestinal disorders (such as ulcers) and Zollinger-Ellison syndrome; prevention of Mendelson syndrome
Who takes it
Adults · Children
Adult dose
Usually, take 1 tablet twice daily, in the morning and at bedtime, regardless of meals. Gastric and duodenal ulcers: Administer 1 tablet twice daily or 2 tablets once daily at bedtime. In particular, a higher healing rate may be achieved in patients with duodenal ulcers by administering 2 tablets twice daily, in the morning and at bedtime. The same dosage applies to combination therapy for ulcers caused by nonsteroidal anti-inflammatory drugs or for the prevention of gastric and duodenal ulcers during long-term use of nonsteroidal anti-inflammatory drugs. Conditions caused by nonsteroidal anti-inflammatory drug use usually heal within 4 weeks, and other ulcers usually heal within 8 weeks, although the healing period may occasionally be longer depending on the patient. For patients with recurrent ulcers who responded well to short-term treatment with this medication, administer 1 tablet once daily at bedtime as maintenance therapy. Reflux esophagitis: Administer 1 tablet twice daily for 8 weeks or 2 tablets once daily at bedtime. However, for patients with severe reflux esophagitis, the dose may be increased to 2 tablets 4 times daily. Zollinger-Ellison syndrome: Initiate treatment with an initial dose of 1 tablet 3 times daily, and increase the dose as needed. For severe disease, up to 6g per day as ranitidine may be administered as directed by a physician. Upper gastrointestinal bleeding due to peptic ulcer, acute stress ulcer, and acute gastric mucosal lesions: When oral administration becomes possible, switch from injection to oral administration and administer 1 tablet twice daily. Administer 1 tablet 2 hours before induction of anesthesia. It is also preferable to administer 1 tablet on the night before surgery. For patients with severe renal impairment and creatinine clearance of 50ml/min or less, take 1 tablet once daily at bedtime. This may vary depending on the patient's condition. Since hemodialysis reduces the blood concentration of the medication, readjust the dosing schedule immediately after hemodialysis.
Child dose
Children 8-18 years of age: 1 tablet per dose (equivalent to ranitidine 2mg/kg), up to twice daily

Ingredients

Manufacturer
Eden Pharma Co., Ltd.

Efficacy & effects

Treatment of gastrointestinal disorders (such as ulcers) and Zollinger-Ellison syndrome; prevention of Mendelson syndrome

  • Gastric ulcers
  • gastritis
  • duodenal ulcers
  • Zollinger-Ellison syndrome
  • gastroesophageal reflux disease
  • Mendelson syndrome
  • post-surgical ulcers
  • gastric and duodenal ulcers due to non-steroidal anti-inflammatory drugs (NSAIDs)
View approved original text

This medication is effectively used for gastrointestinal diseases such as gastric ulcers, gastritis, duodenal ulcers, and Zollinger-Ellison syndrome, as well as for gastroesophageal reflux disease. Additionally, it can prevent Mendelson syndrome when administered preoperatively and assists in the treatment of post-surgical ulcers. It is also applicable for treating ulcers caused by non-steroidal anti-inflammatory drugs (NSAIDs). It helps improve symptoms and treat various gastrointestinal conditions.

How to take

Adult dose

Usually, take 1 tablet twice daily, in the morning and at bedtime, regardless of meals. Gastric and duodenal ulcers: Administer 1 tablet twice daily or 2 tablets once daily at bedtime. In particular, a higher healing rate may be achieved in patients with duodenal ulcers by administering 2 tablets twice daily, in the morning and at bedtime. The same dosage applies to combination therapy for ulcers caused by nonsteroidal anti-inflammatory drugs or for the prevention of gastric and duodenal ulcers during long-term use of nonsteroidal anti-inflammatory drugs. Conditions caused by nonsteroidal anti-inflammatory drug use usually heal within 4 weeks, and other ulcers usually heal within 8 weeks, although the healing period may occasionally be longer depending on the patient. For patients with recurrent ulcers who responded well to short-term treatment with this medication, administer 1 tablet once daily at bedtime as maintenance therapy. Reflux esophagitis: Administer 1 tablet twice daily for 8 weeks or 2 tablets once daily at bedtime. However, for patients with severe reflux esophagitis, the dose may be increased to 2 tablets 4 times daily. Zollinger-Ellison syndrome: Initiate treatment with an initial dose of 1 tablet 3 times daily, and increase the dose as needed. For severe disease, up to 6g per day as ranitidine may be administered as directed by a physician. Upper gastrointestinal bleeding due to peptic ulcer, acute stress ulcer, and acute gastric mucosal lesions: When oral administration becomes possible, switch from injection to oral administration and administer 1 tablet twice daily. Administer 1 tablet 2 hours before induction of anesthesia. It is also preferable to administer 1 tablet on the night before surgery. For patients with severe renal impairment and creatinine clearance of 50ml/min or less, take 1 tablet once daily at bedtime. This may vary depending on the patient's condition. Since hemodialysis reduces the blood concentration of the medication, readjust the dosing schedule immediately after hemodialysis.

Child dose

Children 8-18 years of age: 1 tablet per dose (equivalent to ranitidine 2mg/kg), up to twice daily

Precautions

This medication should not be used in patients undergoing dialysis or those allergic to Ranitidine Hydrochloride. Patients with impaired kidney function may require a reduced dosage or increased dosing interval due to prolonged retention of the medication in the body, and those with liver function issues should use it cautiously. Patients with a history of allergic reactions to this medication or the elderly should also take it with care. While using this medication, serious shock reactions may occur rarely; therefore, patients should be observed carefully, and if abnormal symptoms appear, the medication should be stopped immediately, and appropriate treatment should be sought. If allergic symptoms such as skin rash, urticaria, swelling, fever, respiratory distress, or low blood pressure develop, the administration of the drug must be stopped immediately. Blood tests may show a temporary decrease in white blood cells or platelets, and liver function tests may show a temporary increase or symptoms of hepatitis may appear. Arrhythmias or heart palpitations have been reported rarely, so caution is needed for patients with heart diseases. Gastrointestinal symptoms may include nausea, vomiting, constipation, diarrhea, abdominal bloating, and abdominal pain, and stool color may turn black, although this does not require special treatment. Nervous system side effects such as dizziness, drowsiness, confusion, seizures, insomnia, and headaches may occur infrequently. Cases of gynecomastia or sexual dysfunction have been reported, but direct correlation with this drug is not certain. Joint pain, skin rashes, hair loss, itching, inflammation of the tongue, and even blackening of the tongue can occur rarely, although it usually returns to normal after some time. Long-term use of this medication is not advisable, and patients with kidney disease should consult a doctor or pharmacist before taking it. Therapeutic effects should be confirmed while using the minimum effective dose, and if ineffective, alternative medications should be adopted. Pregnant women or those who may become pregnant should only use this medication if the therapeutic benefits outweigh the risks as its safety is not established. This medication is excreted in breast milk, so breastfeeding should be avoided while taking it. Safety for children has not been fully confirmed, so caution is necessary when using it. Some urine tests may yield false positive results, so it's advisable to use specific testing methods for accurate results. In case of overdose, emergency measures such as vomiting or gastric lavage may be necessary, and in some instances, blood dialysis may be performed to eliminate the drug. This medication can mask symptoms of gastric cancer, so it should only be used after confirming that it is not a malignant disease, and ocular health should be monitored through eye examinations during long-term use.

Side effects

  • Shock
  • skin rash
  • urticaria
  • angioedema
  • fever
  • bronchospasm
  • hypotension
  • leukopenia
  • thrombocytopenia
  • elevated serum creatinine
Show 45 more
  • elevated serum transaminase
  • agranulocytosis
  • pancytopenia
  • bone marrow failure
  • aplastic anemia
  • eosinophilia
  • elevated S-GOT
  • elevated S-GPT
  • elevated r-GPT
  • elevated ALP
  • jaundice hepatitis
  • non-jaundice hepatitis
  • tachycardia
  • bradycardia
  • atrioventricular block
  • premature ventricular contractions
  • nausea
  • vomiting
  • constipation
  • diarrhea
  • abdominal distension
  • abdominal pain
  • loss of appetite
  • dizziness
  • drowsiness
  • confusion
  • seizures
  • agitation
  • depression
  • hallucinations
  • insomnia
  • headache
  • heaviness in the head
  • malaise
  • blurred vision
  • gynecomastia
  • impotence
  • sexual dysfunction
  • arthralgia
  • erythema multiforme
  • rash
  • hair loss
  • pruritus
  • glossitis
  • black tongue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture ingress. It is important to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the medication's efficacy and safety for an extended period.

Appearance and packaging

Appearance

Light green oblong film-coated tablets

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.